title: [Monoclonal antibody against laminin receptor 1 inhibits the pulmonary fibrosis induced by bleomycin in rats].
abstract: OBJECTIVE
  To investigate the effect of the anti-laminin receptor 1 (anti-LAMR1) monoclonal antibody (mAb) on rat pulmonary fibrosis induced by bleomycin.
  
  
  METHODS
  Seventy-two male Wistar rats were randomly divided into 3 groups: LAMR1 mAb group (group L), control group (group C) and model group (group M). All rats were injected with bleomycin via tracheal instillation (5 mg/kg body mass) to induce pulmonary fibrosis. Then, the rats were treated with anti-LAMR1 mAb (group L), dexamethasone (group C), normal saline (group M), three times each week via intraperitoneal injection. Eight rats in each group were sacrificed at the 7, 14, 28 days. Histological changes of the lungs were evaluated by HE staining. The expression of surfactant protein A (SP-A) in the lung tissue was measured by immunohistochemistry. The expression of hydroxyproline (Hyp) in serum was measured by ELISA. The expressions of MMP-9 and TGF-β1 mRNA were evaluated by PCR.
  
  
  RESULTS
  Compared with the other two groups, group M presented more apparent alveolitis and the higher expression of hydroxyproline in serum, the lower expression of SP-A, and the higher expressions of MMP-9 and TGF-β1 mRNA in the lung tissue.
  
  
  CONCLUSIONS
  LAMR1 mAb can evidently alleviate pulmonary fibrosis induced by bleomycin in rats.
authors.affiliation: Department of Respiratory Medicine, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Dongling
authors.initials: D
authors.lastname: Chen
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: Yanmei
authors.initials: Y
authors.lastname: Feng
authors.forename: Mi
authors.initials: M
authors.lastname: Zhou
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Han
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001761:Bleomycin / Q000009:adverse effects; D004195:Disease Models, Animal; D006909:Hydroxyproline / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism*; D037662:Pulmonary Surfactant-Associated Protein A / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017474:Receptors, Laminin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013997:Time Factors; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D037662:Pulmonary Surfactant-Associated Protein A; D012333:RNA, Messenger; D017474:Receptors, Laminin; D053773:Transforming Growth Factor beta1; D001761:Bleomycin; D020780:Matrix Metalloproteinase 9; D006909:Hydroxyproline